Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-09-28 23:49:22 - browse：75479

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Health care court cases: Humana, Sutter, Novant

focus

WSS

STAT Virtual Event: ASCO Recap, Live!

The (many) problems with a new study criticizing cancer screening

Readers discuss the intersection of pregnancy and addiction

Moderna says combo Covid

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

explore

Wikipedia

explore

Alkermes shareholders re

A rare thyroid diagnosis led to unexpected, all

United colonoscopy coverage change 'may cost lives,' doctors say

How generative AI is inspiring dreams of a health data revolution

Psychedelics group wrestles with new pharma identity

Snackable artificial intelligence, expert AI, and the pharma industry

Peter Hotez and the public health issue of online harassment

Curing rare childhood diseases will falter unless Congress steps up

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How generative AI is inspiring dreams of a health data revolution

Wikipedia

A rare thyroid diagnosis led to unexpected, all

Weighted lottery helped low

How to fix cancer clinical trials' diversity problem

What drug price negotiations mean for Medicare Part D

NIH nominee Bertagnolli will get October confirmation hearing

Cigna wins case to block Amy Bricker's move to CVS

focus

focus

knowledge

focus